Professor of Hematology and Oncology, Mayo Medical School
Oncology
Dr. James N. Ingle, MD
|
|
Give Review
Dr. James N. Ingle is an expert in the field of Oncology. He studied medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Redbook Magazine: Top Breast Cancer Doctors" and "Whos Who in Medicine and Healthcare". James N. Ingle, MD has written publications. He has 101 publications published with PubMed. The lastest publication is: 'Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.' He is registered with Medicare and accepts Medicare payments.
Publications
- Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
- Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
- A polygenic risk score for breast Cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
- Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer...
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer.
- Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24-/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative Breast can...
- Reply to P. Niravath et al.
- Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder.
- Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
- Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast Cancer.
- Genome-wide association study identifies 25 known breast Cancer susceptibility loci as risk factors for triple negative breast Cancer.
- TGFβ Inducible Early Gene-1 Plays an Important Role in Mediating Estrogen Signaling in the Skeleton.
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer.
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations.
- Postmenopausal women with hormone receptor-positive breast Cancer: Balancing benefit and toxicity from aromatase inhibitors.
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker.
- Pharmacogenomics of endocrine therapy in breast Cancer.
- A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the Breast.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- Mammographic Breast density response to aromatase inhibition.
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast Cancer stem cells.
- Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens.
- Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast Cancer cells.
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
- Impact of premenopausal status at breast Cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
- Two-Phase Designs to Follow-Up Genome-Wide Association Signals With DNA Resequencing Studies.
- The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER?(+) breast Cancer cells.
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
- Identification of a novel percent mammographic density locus at 12q24.
- Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
- Automated discovery of drug treatment patterns for endocrine therapy of breast Cancer within an electronic medical record.
- Development, characterization and applications of a novel estrogen receptor beta monoclonal antibody.
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast Cancer.
- CYP2D6 and Tamoxifen: Awaiting the Denouement.
- SULT1A1, CYP2C19 and disease-free survival in early breast Cancer patients receiving tamoxifen.
- Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score.
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast Cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Tissue composition of mammographically dense and non-dense Breast tissue.
- p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905).
- TGF{beta}/TNF{alpha}-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype.
- Estrogen receptor-beta sensitizes breast Cancer cells to the anti-estrogenic actions of endoxifen.
- Overview of adjuvant trials of aromatase inhibitors in early breast Cancer.
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast Cancer from the north central Cancer treatment group N9831 adjuvant trastuzu...
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
- Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive rece...
- A promising approach for treatment of tumor-induced bone Diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
- Coprescription of tamoxifen and medications that inhibit CYP2D6.
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast Cancer.
- Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated...
- A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.
- Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast Cancer.
- Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast Cancer patients to neoadjuvant therapy with aromatase inhibitors.
- Local excision alone without irradiation for ductal carcinoma in situ of the Breast: a trial of the Eastern Cooperative Oncology Group.
- Association between CYP2D6 polymorphisms and outcomes among women with early stage breast Cancer treated with tamoxifen.
- Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging.
- Menstrual cycle and surgical treatment of breast Cancer: findings from the NCCTG N9431 study.
- Immune-induced epithelial to mesenchymal transition in vivo generates breast Cancer stem cells.
- The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast Cancer cells.
- Endocrine therapy in 2009: consideration of the tumor and the host.
- Rcl is a novel ETV1/ER81 target gene upregulated in Breast tumors.
- Extended adjuvant endocrine therapy in breast Cancer: current status and future directions.
- Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
- Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activa...
- The molecular etiology of breast Cancer: evidence from biomarkers of risk.
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat Analysis of the National Surgical Adjuvant Breast And Bowe...
- Efficacy, toxicity, and quality of life in older women with early-stage breast Cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup...
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast Cancer who complete 5 years of tamoxifen.
- Molecular Analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuva...
- Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast Cancer.
- Pharmacogenomics of tamoxifen and aromatase inhibitors.
- Endocrine and targeted manipulation of breast Cancer: summary statement for the Sixth Cambridge Conference.
- National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast Cancer in postmenopausal women.
- A multidisciplinary approach to the management of breast Cancer, part 2: therapeutic considerations.
- Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
- A multidisciplinary approach to the management of breast Cancer, part 1: prevention and diagnosis.
- A phase II study of ABT-510 (thrombospondin-1 Analog) for the treatment of metastatic melanoma.
- A comprehensive examination of CYP19 variation and Breast density.
- Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast Cancer: final analysis from INT-0137 (S9313).
- Gene-expression-based predictors for breast Cancer.
- A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell Carcinoma.
- p27(Kip1) and cyclin E expression and breast Cancer survival after treatment with adjuvant chemotherapy.
- Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast Cancer.
- Effect of letrozole versus placebo on bone mineral density in women with primary breast Cancer completing 5 or more years of adjuvant tamoxifen: a companion study to N...
- Peptide vaccination of patients with metastatic Melanoma: improved clinical outcome in patients demonstrating effective immunization.
- HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
- A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
- Adjuvant endocrine therapy for postmenopausal women with early breast Cancer.
- Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic Melanoma.
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
- Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastat...
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast Cancer.
- Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast Cancer: updated findings from NCIC CTG MA.17.
- Evaluation of a panel of tumor markers for molecular detection of circulating Cancer cells in women with suspected breast Cancer.
- Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast Cancer on NCIC CTG MA.27.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins Hospital
National Institutes Of Health Clinical Center
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Redbook Magazine: Top Breast Cancer Doctors
- Whos Who in Medicine and Healthcare
Education
-
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1356327670 | |
| NPPES Provider LastName | INGLE | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 108.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356327670 |
| Last Name Of The Provider | INGLE |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Gary A. Croghan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Frytak, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michaela S. Banck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditya Bardia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Moynihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn C. Hartmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Morris A. Gertz |